<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d1 20130915//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Ann Rheum Dis</journal-id><journal-id journal-id-type="iso-abbrev">Ann. Rheum. Dis</journal-id><journal-id journal-id-type="hwp">annrheumdis</journal-id><journal-id journal-id-type="publisher-id">ard</journal-id><journal-title-group><journal-title>Annals of the Rheumatic Diseases</journal-title></journal-title-group><issn pub-type="ppub">0003-4967</issn><issn pub-type="epub">1468-2060</issn><publisher><publisher-name>BMJ Publishing Group</publisher-name><publisher-loc>BMA House, Tavistock Square, London, WC1H 9JR</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5036214</article-id><article-id pub-id-type="pmid">26613768</article-id><article-id pub-id-type="publisher-id">annrheumdis-2015-207872</article-id><article-id pub-id-type="doi">10.1136/annrheumdis-2015-207872</article-id><article-categories><subj-group subj-group-type="hwp-journal-coll"><subject>1506</subject></subj-group><subj-group subj-group-type="heading"><subject>Clinical and Epidemiological Research</subject></subj-group><series-title>Extended report</series-title></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Gabay</surname><given-names>Cem</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>McInnes</surname><given-names>Iain B</given-names></name><xref ref-type="aff" rid="af2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kavanaugh</surname><given-names>Arthur</given-names></name><xref ref-type="aff" rid="af3">3</xref></contrib><contrib contrib-type="author"><name><surname>Tuckwell</surname><given-names>Katie</given-names></name><xref ref-type="aff" rid="af4">4</xref></contrib><contrib contrib-type="author"><name><surname>Klearman</surname><given-names>Micki</given-names></name><xref ref-type="aff" rid="af5">5</xref></contrib><contrib contrib-type="author"><name><surname>Pulley</surname><given-names>Jennifer</given-names></name><xref ref-type="aff" rid="af4">4</xref></contrib><contrib contrib-type="author"><name><surname>Sattar</surname><given-names>Naveed</given-names></name><xref ref-type="aff" rid="af2">2</xref></contrib></contrib-group><aff id="af1">
<label>1</label><institution>University Hospitals</institution>, <addr-line>Geneva</addr-line>, <country>Switzerland</country></aff><aff id="af2">
<label>2</label><institution>University of Glasgow</institution>, <addr-line>Glasgow</addr-line>, <country>UK</country></aff><aff id="af3">
<label>3</label><institution>University of California</institution>, <addr-line>San Diego, California</addr-line>, <country>USA</country></aff><aff id="af4">
<label>4</label><institution>Roche Products Ltd</institution>, <addr-line>Welwyn Garden City</addr-line>, <country>UK</country></aff><aff id="af5">
<label>5</label><institution>Genentech</institution>, <addr-line>South San Francisco, California</addr-line>, <country>USA</country></aff><author-notes><fn><p><text><SENT sid="1" pm="."><plain>Handling editor Tore K Kvien </plain></SENT>
</text></p></fn><corresp><label>Correspondence to</label> Professor Cem Gabay, Division of Rheumatology, University Hospitals of Geneva, 26 Avenue de Beau-Séjour, Geneva 14 CH-1211, Switzerland; <email>cem.gabay@hcuge.ch</email></corresp></author-notes><pub-date pub-type="ppub"><month>10</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>27</day><month>11</month><year>2015</year></pub-date><volume>75</volume><issue>10</issue><fpage>1806</fpage><lpage>1812</lpage><history><date date-type="received"><day>30</day><month>4</month><year>2015</year></date><date date-type="rev-recd"><day>28</day><month>10</month><year>2015</year></date><date date-type="accepted"><day>1</day><month>11</month><year>2015</year></date></history><permissions><copyright-statement>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/</copyright-statement><copyright-year>2016</copyright-year><license license-type="open-access"><license-p>This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link></license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="annrheumdis-2015-207872.pdf"/><abstract><sec><title><text><SENT sid="2" pm="."><plain>Objective </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="3" pm="."><plain>Compare changes in lipids and lipid-associated cardiovascular (CV) risk markers in patients with rheumatoid arthritis (RA) treated with tocilizumab or adalimumab. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="4" pm="."><plain>Methods </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="5" pm="."><plain>Post-hoc analysis was performed in patients with RA who received tocilizumab intravenously every 4 weeks or adalimumab subcutaneously every 2 weeks for 24 weeks in the ADACTA trial. </plain></SENT>
<SENT sid="6" pm="."><plain>Lipid and lipid-associated CV risk biomarkers, including high-density lipoprotein-associated serum amyloid-A (HDL-SAA), secretory phospholipase A2 IIA (sPLA2 IIA) and lipoprotein(a) (Lp(a)), were measured at baseline and at week 8. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="7" pm="."><plain>Results </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="8" pm="."><plain>The study included 162 patients treated with tocilizumab and 162 patients treated with adalimumab; HDL-SAA and sPLA2 IIA were measured in a subpopulation of 87 and 97 patients, respectively. </plain></SENT>
<SENT sid="9" pm="."><plain>Greater increases in mean low-density lipoprotein cholesterol (LDL-C) (0.46 mmol/L (95% CI 0.30 to 0.62)), high-density lipoprotein cholesterol (HDL-C) (0.07 mmol/L (0.001 to 0.14)), total cholesterol (TC) (0.67 mmol/L (0.47 to 0.86)), triglycerides (0.24 mmol/L (0.10 to 0.38)) and TC:HDL ratio (0.27 (0.12 to 0.42)) occurred with tocilizumab from baseline to 8 weeks. </plain></SENT>
<SENT sid="10" pm="."><plain>HDL-SAA, sPLA2 IIA and Lp(a) decreased more with tocilizumab than adalimumab. </plain></SENT>
<SENT sid="11" pm="."><plain>Median changes from baseline to week 8 were –3.2 and –1.1 mg/L (p=0.0077) for HDL-SAA and –4.1 and –1.3 ng/mL (p&lt;0.0001) for sPLA2 IIA; difference in adjusted means was –7.12 mg/dL (p&lt;0.0001) for Lp(a). </plain></SENT>
<SENT sid="12" pm="."><plain>Similar results were observed in efficacy responders and non-responders per American College of Rheumatology and European League against Rheumatism criteria. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="13" pm="."><plain>Conclusion </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="14" pm="."><plain>LDL-C and HDL-C increased more with tocilizumab than adalimumab. </plain></SENT>
<SENT sid="15" pm="."><plain>HDL-SAA, sPLA2 IIA and Lp(a) decreased more with tocilizumab. </plain></SENT>
<SENT sid="16" pm="."><plain>Lipid change effects of interleukin-6 and tumour necrosis factor (TNF) inhibition, manifest by their net impact on lipids and lipoproteins, are not synonymous; the clinical significance is unclear and requires further study. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="17" pm="."><plain>Trial registration number </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="18" pm="."><plain>NCT01119859.; post-results </plain></SENT>
</text></SecTag></p></sec></abstract><SecTag type="KEYWORD"><kwd-group><kwd>Lipids</kwd><kwd>Cardiovascular Disease</kwd><kwd>Inflammation</kwd><kwd>Rheumatoid Arthritis</kwd></kwd-group></SecTag><custom-meta-group><custom-meta><meta-name>special-feature</meta-name><meta-value>unlocked</meta-value></custom-meta></custom-meta-group></article-meta></front><body><SecTag type="INTRO"><sec sec-type="intro" id="s1"><title><text><SENT sid="19" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="20" pm="."><plain>Patients with rheumatoid arthritis (RA) are at increased risk of cardiovascular disease (CVD) compared with the general population.1 2 Traditional risk factors for CVD do not appear to fully explain this increased risk,3 and additional factors, including inflammation, may contribute to CVD risk in RA.4 5 The impact of inflammation on lipid levels is complex and may manifest as changes in total cholesterol (TC) levels and in lipid particle–associated proteins, such as serum amyloid A (SAA) and secretory phospholipase A2 IIA (sPLA2 IIA); both are identified biomarkers of increased cardiovascular (CV) risk.6–8 Patients with severe, untreated RA may have very low lipid levels, which is paradoxical when considering their increased risk of CVD.9 In contrast, treatment of active disease can lead to elevated levels of TC, low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) in conjunction with reduced levels of inflammation.9 </plain></SENT>
</text></p><p><text><SENT sid="21" pm="."><plain>Lipoprotein(a) (Lp(a)) levels are increased in patients with RA.10 The association of Lp(a) with CVD in the general population has been assessed through genetic and Mendelian randomisation studies.11–13 These studies strongly point to Lp(a) as a causal agent in the process of atherogenesis.11–14 </plain></SENT>
</text></p><p><text><SENT sid="22" pm="."><plain>Moderate early elevations in LDL-C, HDL-C and triglyceride levels were reported in Phase II and Phase III clinical trials of patients with RA treated with the interleukin-6 (IL-6) receptor inhibitor tocilizumab (TCZ); the TC:HDL-C ratio either decreased or remained unchanged.15 In contrast, a decline in Lp(a) with TCZ treatment and a change in HDL protein composition occurred.16 Lipid changes have also been reported in patients with RA treated with tumour necrosis factor (TNF)-α inhibitors.17 Patients with RA treated with adalimumab had increased HDL-C and apolipoprotein A1 levels, with no change in LDL-C or triglyceride levels, and improvement in atherogenic ratios.18 19 Data on the effect of TNF-α blockers on Lp(a) are mixed, though most did suggest a reduction.19–23 Described here is a post-hoc analysis of data from a clinical trial that compared IL-6 and TNF-α signalling inhibition to assess the impact of these therapeutic strategies on lipid-associated CV risk biomarkers and their relationship to treatment response. </plain></SENT>
<SENT sid="23" pm="."><plain>The dearth of such comparator trials despite an urgent need for better understanding of any differential effects of these agents on CV risk parameters makes this analysis important. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec sec-type="methods" id="s2"><title><text><SENT sid="24" pm="."><plain>Patients and methods </plain></SENT>
</text></title><sec id="s2a"><title><text><SENT sid="25" pm="."><plain>Patients </plain></SENT>
</text></title><p><text><SENT sid="26" pm="."><plain>This post-hoc study included patients from the ADACTA trial (ClinicalTrials.gov number NCT01119859). </plain></SENT>
<SENT sid="27" pm="."><plain>ADACTA was a Phase IV study that assessed the efficacy of TCZ as monotherapy compared with adalimumab as monotherapy in adults who had RA for ≥6 months and who were intolerant of or not good candidates for continued use of methotrexate (MTX).24 A total of 326 patients were randomly assigned 1:1 to receive either TCZ 8 mg/kg monotherapy intravenously every 4 weeks plus subcutaneous placebo every 2 weeks or adalimumab 40 mg monotherapy subcutaneously every 2 weeks plus intravenous placebo every 4 weeks for 24 weeks. </plain></SENT>
<SENT sid="28" pm="."><plain>Patients had to discontinue all synthetic disease-modifying antirheumatic drugs (DMARDs) within an appropriate washout period before baseline; any patient requiring treatment with a synthetic or biological DMARD was withdrawn from the study.24 Analyses of core lipids and Lp(a) were performed in the ADACTA safety population, which included all patients who received at least one dose of study medication and had at least one post-dose safety assessment. </plain></SENT>
<SENT sid="29" pm="."><plain>Additional analyses of lipid-associated CV risk biomarkers were performed in 184 patients (97 adalimumab, 87 TCZ) who consented to donate serum bio-repository samples for further exploratory analysis and who provided both baseline and week 8 samples. </plain></SENT>
<SENT sid="30" pm="."><plain>Week 8 samples provide a larger sample size than do later time points, and previous studies have shown that lipid changes observed after 6 weeks remain stable with continued TCZ treatment.25 </plain></SENT>
</text></p></sec><sec id="s2b"><title><text><SENT sid="31" pm="."><plain>Assessments </plain></SENT>
</text></title><p><text><SENT sid="32" pm="."><plain>Core lipid panel (LDL-C, HDL-C, TC and triglycerides) and lipid-associated CV risk biomarker levels (Lp(a), HDL-SAA and sPLA2 IIA) were analysed in serum samples obtained at baseline and at week 8. </plain></SENT>
<SENT sid="33" pm="."><plain>Week 8 was selected because of the limited availability of bio-repository samples later in the study although data for Lp(a) and core lipids were available for later time points. </plain></SENT>
<SENT sid="34" pm="."><plain>With the exception of LDL, which was calculated using the formula TC−HDL-C−(triglycerides/5), the core lipid panel was measured using the β-quantification method. </plain></SENT>
<SENT sid="35" pm="."><plain>The core lipid panel and Lp(a) was analysed by Covance Central Laboratory Services (Indianapolis, Indiana, USA). </plain></SENT>
<SENT sid="36" pm="."><plain>Assays for HDL-SAA and sPLA2 IIA levels were performed at Pacific Biometrics (Seattle, Washington, USA). </plain></SENT>
</text></p><p><text><SENT sid="37" pm="."><plain>sPLA2 IIA was determined with the use of an enzyme immunoassay (EIA) kit (Cayman Chemical, Ann Arbor, Michigan, USA) by coupling a monoclonal capture antibody with detection by acetylcholinesterase/Fab conjugate and 5′5-dithiobis 2-nitrobenzoic acid (DTNB). </plain></SENT>
<SENT sid="38" pm="."><plain>EDTA serum Lp(a) (Denka Seiken, Tokyo, Japan) was quantified using immunoturbidimetric assay kits. </plain></SENT>
<SENT sid="39" pm="."><plain>These assays were performed with a Roche Modular P autoanalyzer (Roche Diagnostics, Indianapolis, Indiana, USA). </plain></SENT>
</text></p><p><text><SENT sid="40" pm="."><plain>For determination of HDL-SAA, serum HDL particles were isolated by polyethylene glycol 8000 (PEG-8000; Promega, Madison, Wisconsin, USA) precipitation, as described by Chiba et al.26 Briefly, equal volumes of 13.0% PEG (P-4463; Sigma-Aldrich, St Louis, Missouri, USA) were mixed to precipitate non-HDL proteins and lipoproteins. </plain></SENT>
<SENT sid="41" pm="."><plain>After centrifugation for 5 min at 18 000 g, supernate SAA was determined by EIA (Abazyme; Needham, Massachusetts, USA). </plain></SENT>
<SENT sid="42" pm="."><plain>An anti-SAA monoclonal capture and a horseradish peroxidase-conjugated polyclonal antibody were used with 3,3′,5,5′-tetramethylbenzidine (TMB) detection. </plain></SENT>
</text></p></sec><sec id="s2c"><title><text><SENT sid="43" pm="."><plain>Statistical analyses </plain></SENT>
</text></title><p><text><SENT sid="44" pm="."><plain>Differences between TCZ and adalimumab in change from baseline to week 8 in LDL-C, HDL-C, TC, triglycerides, TC:HDL ratio and Lp(a) were assessed using a post-hoc analysis of covariance model adjusted for baseline laboratory parameters. </plain></SENT>
</text></p><p><text><SENT sid="45" pm="."><plain>Differences in change from baseline to week 8 in HDL-SAA and sPLA2 IIA were assessed using the Kruskal–Wallis test. </plain></SENT>
<SENT sid="46" pm="."><plain>Log transformation of the data was investigated because of the skewed distribution of these two parameters. </plain></SENT>
<SENT sid="47" pm="."><plain>The transformation did not allow the parameters to be normally distributed; therefore, the non-parametric statistical method of the Kruskal–Wallis test was used to account for the skewed distribution of the data. </plain></SENT>
<SENT sid="48" pm="."><plain>Change from baseline to week 8 was summarised and was also split by efficacy responders. </plain></SENT>
<SENT sid="49" pm="."><plain>Week 24 American College of Rheumatology (ACR) 20, ACR50 and European League against Rheumatism (EULAR) good/moderate responders and non-responders were used to analyse HDL-SAA, sPLA2 IIA and Lp(a) levels by efficacy. </plain></SENT>
<SENT sid="50" pm="."><plain>Change in Lp(a) from &gt;50 mg/dL at baseline to ≤50 mg/dL at week 8 was summarised based on recommendations that suggest Lp(a) levels should ideally be &lt;50 mg/dL in patients at intermediate or high risk of CVD/coronary heart disease (CHD).27 All statistical analyses were post-hoc; therefore, no adjustments were made for multiple testing, and no statistical significance can be claimed. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="RESULTS"><sec sec-type="results" id="s3"><title><text><SENT sid="51" pm="."><plain>Results </plain></SENT>
</text></title><p><text><SENT sid="52" pm="."><plain>The ADACTA safety population consisted of 324 patients who were intolerant of MTX or for whom MTX was inappropriate. </plain></SENT>
<SENT sid="53" pm="."><plain>The bio-repository population consisted of 184 patients from the ADACTA safety population. </plain></SENT>
<SENT sid="54" pm="."><plain>Baseline demographics and disease characteristics were similar between the two treatment arms and between the safety and bio-repository populations (see online supplementary table S1). </plain></SENT>
<SENT sid="55" pm="."><plain>Core lipid parameters, including LDL-C, HDL-C, TC, triglyceride levels and TC:HDL ratio, increased from baseline to week 8 with TCZ monotherapy; numerically smaller changes were observed for these lipids with adalimumab monotherapy. </plain></SENT>
</text></p><p><text><SENT sid="56" pm="."><plain>Differences in mean (95% CI) change from baseline between arms were as follows: 0.46 mmol/L (0.30 to 0.62; p&lt;0.0001) for LDL-C; 0.07 mmol/L (0.001 to 0.14; p=0.0453) for HDL-C; 0.67 mmol/L (0.47 to 0.86; p&lt;0.0001) for TC; 0.24 mmol/L (0.10 to 0.38; p=0.0008) for triglycerides and 0.27 (0.12 to 0.42; p=0.0005) for TC:HDL ratio (table 1). </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="ANNRHEUMDIS2015207872TB1" orientation="portrait" position="float"><label>Table 1</label><caption><p><text><SENT sid="57" pm="."><plain>Mean change from baseline to week 8* in lipid parameters (safety population) </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead valign="bottom"><tr><th align="left" rowspan="1" colspan="1"><text><SENT sid="58" pm="."><plain>Statistic </plain></SENT>
</text></th><th align="left" colspan="2" rowspan="1"><text><SENT sid="59" pm="."><plain>ADA 40 mg SC q2w, n=162 </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="60" pm="."><plain>TCZ 8 mg/kg IV q4w, n=162 </plain></SENT>
</text></th></tr></thead><tbody><tr><td colspan="4" rowspan="1"><text><SENT sid="61" pm="."><plain>Total cholesterol, mmol/L </plain></SENT>
</text></td></tr><tr><td colspan="4" rowspan="1"><text><SENT sid="62" pm="."><plain> Baseline </plain></SENT>
</text></td></tr><tr><td rowspan="1" colspan="1"><text><SENT sid="63" pm="."><plain>  n </plain></SENT>
</text></td><td colspan="2" rowspan="1"><text><SENT sid="64" pm="."><plain>145 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="65" pm="."><plain>150 </plain></SENT>
</text></td></tr><tr><td rowspan="1" colspan="1"><text><SENT sid="66" pm="."><plain>  Mean (SD) </plain></SENT>
</text></td><td colspan="2" rowspan="1"><text><SENT sid="67" pm="."><plain>4.94 (1.06) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="68" pm="."><plain>5.13 (1.11) </plain></SENT>
</text></td></tr><tr><td colspan="4" rowspan="1"><text><SENT sid="69" pm="."><plain>Change from baseline to week 8 </plain></SENT>
</text></td></tr><tr><td rowspan="1" colspan="1"><text><SENT sid="70" pm="."><plain> n </plain></SENT>
</text></td><td colspan="2" rowspan="1"><text><SENT sid="71" pm="."><plain>129 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="72" pm="."><plain>138 </plain></SENT>
</text></td></tr><tr><td rowspan="1" colspan="1"><text><SENT sid="73" pm="."><plain> Mean (SD) </plain></SENT>
</text></td><td colspan="2" rowspan="1"><text><SENT sid="74" pm="."><plain>0.17 (0.65) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="75" pm="."><plain>0.79 (0.97) </plain></SENT>
</text></td></tr><tr><td rowspan="1" colspan="1"><text><SENT sid="76" pm="."><plain> Difference in adjusted means (95% CI)† </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="77" pm="."><plain>0.67 (0.47 to 0.86) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"><text><SENT sid="78" pm="."><plain> p Value‡ </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="79" pm="."><plain>&lt;0.0001 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr><td colspan="4" rowspan="1"><text><SENT sid="80" pm="."><plain>Triglycerides, mmol/L </plain></SENT>
</text></td></tr><tr><td colspan="4" rowspan="1"><text><SENT sid="81" pm="."><plain> Baseline </plain></SENT>
</text></td></tr><tr><td rowspan="1" colspan="1"><text><SENT sid="82" pm="."><plain>  n </plain></SENT>
</text></td><td colspan="2" rowspan="1"><text><SENT sid="83" pm="."><plain>145 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="84" pm="."><plain>150 </plain></SENT>
</text></td></tr><tr><td rowspan="1" colspan="1"><text><SENT sid="85" pm="."><plain>  Mean (SD) </plain></SENT>
</text></td><td colspan="2" rowspan="1"><text><SENT sid="86" pm="."><plain>1.39 (0.69) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="87" pm="."><plain>1.48 (0.97) </plain></SENT>
</text></td></tr><tr><td colspan="4" rowspan="1"><text><SENT sid="88" pm="."><plain>Change from baseline to week 8 </plain></SENT>
</text></td></tr><tr><td rowspan="1" colspan="1"><text><SENT sid="89" pm="."><plain> n </plain></SENT>
</text></td><td colspan="2" rowspan="1"><text><SENT sid="90" pm="."><plain>129 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="91" pm="."><plain>138 </plain></SENT>
</text></td></tr><tr><td rowspan="1" colspan="1"><text><SENT sid="92" pm="."><plain> Mean (SD) </plain></SENT>
</text></td><td colspan="2" rowspan="1"><text><SENT sid="93" pm="."><plain>0.07 (0.47) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="94" pm="."><plain>0.29 (0.68) </plain></SENT>
</text></td></tr><tr><td rowspan="1" colspan="1"><text><SENT sid="95" pm="."><plain> Difference in adjusted means (95% CI)† </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="96" pm="."><plain>0.24 (0.10–0.38) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"><text><SENT sid="97" pm="."><plain> p Value‡ </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="98" pm="."><plain>0.0008 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr><td colspan="4" rowspan="1"><text><SENT sid="99" pm="."><plain>HDL-C, mmol/L </plain></SENT>
</text></td></tr><tr><td colspan="4" rowspan="1"><text><SENT sid="100" pm="."><plain> Baseline </plain></SENT>
</text></td></tr><tr><td rowspan="1" colspan="1"><text><SENT sid="101" pm="."><plain>  n </plain></SENT>
</text></td><td colspan="2" rowspan="1"><text><SENT sid="102" pm="."><plain>145 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="103" pm="."><plain>149 </plain></SENT>
</text></td></tr><tr><td rowspan="1" colspan="1"><text><SENT sid="104" pm="."><plain>  Mean (SD) </plain></SENT>
</text></td><td colspan="2" rowspan="1"><text><SENT sid="105" pm="."><plain>1.52 (0.38) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="106" pm="."><plain>1.56 (0.48) </plain></SENT>
</text></td></tr><tr><td colspan="4" rowspan="1"><text><SENT sid="107" pm="."><plain>Change from baseline to week 8 </plain></SENT>
</text></td></tr><tr><td rowspan="1" colspan="1"><text><SENT sid="108" pm="."><plain> n </plain></SENT>
</text></td><td colspan="2" rowspan="1"><text><SENT sid="109" pm="."><plain>129 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="110" pm="."><plain>137 </plain></SENT>
</text></td></tr><tr><td rowspan="1" colspan="1"><text><SENT sid="111" pm="."><plain> Mean (SD) </plain></SENT>
</text></td><td colspan="2" rowspan="1"><text><SENT sid="112" pm="."><plain>0.07 (0.25) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="113" pm="."><plain>0.14 (0.31) </plain></SENT>
</text></td></tr><tr><td rowspan="1" colspan="1"><text><SENT sid="114" pm="."><plain> Difference in adjusted means (95% CI)† </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="115" pm="."><plain>0.07 (0.001 to 0.14) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"><text><SENT sid="116" pm="."><plain> p Value‡ </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="117" pm="."><plain>0.0453 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr><td colspan="4" rowspan="1"><text><SENT sid="118" pm="."><plain>LDL-C, mmol/L </plain></SENT>
</text></td></tr><tr><td colspan="4" rowspan="1"><text><SENT sid="119" pm="."><plain> Baseline </plain></SENT>
</text></td></tr><tr><td rowspan="1" colspan="1"><text><SENT sid="120" pm="."><plain>  n </plain></SENT>
</text></td><td colspan="2" rowspan="1"><text><SENT sid="121" pm="."><plain>144 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="122" pm="."><plain>146 </plain></SENT>
</text></td></tr><tr><td rowspan="1" colspan="1"><text><SENT sid="123" pm="."><plain>  Mean (SD) </plain></SENT>
</text></td><td colspan="2" rowspan="1"><text><SENT sid="124" pm="."><plain>2.78 (0.89) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="125" pm="."><plain>2.88 (0.87) </plain></SENT>
</text></td></tr><tr><td colspan="4" rowspan="1"><text><SENT sid="126" pm="."><plain>Change from baseline to week 8 </plain></SENT>
</text></td></tr><tr><td rowspan="1" colspan="1"><text><SENT sid="127" pm="."><plain> n </plain></SENT>
</text></td><td colspan="2" rowspan="1"><text><SENT sid="128" pm="."><plain>128 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="129" pm="."><plain>133 </plain></SENT>
</text></td></tr><tr><td rowspan="1" colspan="1"><text><SENT sid="130" pm="."><plain> Mean (SD) </plain></SENT>
</text></td><td colspan="2" rowspan="1"><text><SENT sid="131" pm="."><plain>0.07 (0.53) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="132" pm="."><plain>0.52 (0.79) </plain></SENT>
</text></td></tr><tr><td rowspan="1" colspan="1"><text><SENT sid="133" pm="."><plain> Difference in adjusted means (95% CI)† </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="134" pm="."><plain>0.46 (0.30 to 0.62) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"><text><SENT sid="135" pm="."><plain> p Value‡ </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="136" pm="."><plain>&lt;0.0001 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr><td colspan="4" rowspan="1"><text><SENT sid="137" pm="."><plain>Total cholesterol/HDL ratio </plain></SENT>
</text></td></tr><tr><td colspan="4" rowspan="1"><text><SENT sid="138" pm="."><plain> Baseline </plain></SENT>
</text></td></tr><tr><td rowspan="1" colspan="1"><text><SENT sid="139" pm="."><plain>  n </plain></SENT>
</text></td><td colspan="2" rowspan="1"><text><SENT sid="140" pm="."><plain>145 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="141" pm="."><plain>149 </plain></SENT>
</text></td></tr><tr><td rowspan="1" colspan="1"><text><SENT sid="142" pm="."><plain>  Mean (SD) </plain></SENT>
</text></td><td colspan="2" rowspan="1"><text><SENT sid="143" pm="."><plain>3.40 (0.97) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="144" pm="."><plain>3.51 (1.11) </plain></SENT>
</text></td></tr><tr><td colspan="4" rowspan="1"><text><SENT sid="145" pm="."><plain>Change from baseline to week 8 </plain></SENT>
</text></td></tr><tr><td rowspan="1" colspan="1"><text><SENT sid="146" pm="."><plain> n </plain></SENT>
</text></td><td colspan="2" rowspan="1"><text><SENT sid="147" pm="."><plain>129 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="148" pm="."><plain>137 </plain></SENT>
</text></td></tr><tr><td rowspan="1" colspan="1"><text><SENT sid="149" pm="."><plain> Mean (SD) </plain></SENT>
</text></td><td colspan="2" rowspan="1"><text><SENT sid="150" pm="."><plain>–0.01(0.51) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="151" pm="."><plain>0.24 (0.71) </plain></SENT>
</text></td></tr><tr><td rowspan="1" colspan="1"><text><SENT sid="152" pm="."><plain> Difference in adjusted means (95% CI)† </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="153" pm="."><plain>0.27 (0.12 to 0.42) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"><text><SENT sid="154" pm="."><plain> p Value‡ </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="155" pm="."><plain>0.0005 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn><p><text><SENT sid="156" pm="."><plain>*Includes only patients with both baseline and week 8 worst fasting values. </plain></SENT>
</text></p></fn><fn><p><text><SENT sid="157" pm="."><plain>†Difference and 95% CI were based on adjusted least square means (TCZ-ADA). </plain></SENT>
</text></p></fn><fn><p><text><SENT sid="158" pm="."><plain>‡ANCOVA model was adjusted for baseline laboratory parameter. p Values were unadjusted for multiple testing; therefore, no statistical significance can be claimed. </plain></SENT>
</text></p></fn><fn><p><text><SENT sid="159" pm="."><plain>ADA, adalimumab; ANCOVA, analysis of covariance; HDL, high-density lipoprotein; HDL-C, high-density lipoprotein cholesterol; IV, intravenous; LDL, low-density lipoprotein; LDL-C, low-density lipoprotein cholesterol; q2w, every 2 weeks; q4w, every 4 weeks; SC, subcutaneous; TCZ, tocilizumab. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><p><text><SENT sid="160" pm="."><plain>Reductions in HDL-SAA levels were observed from baseline to week 8 in patients treated with TCZ monotherapy and in those treated with adalimumab monotherapy. </plain></SENT>
<SENT sid="161" pm="."><plain>A greater treatment effect was observed in the TCZ group; median (IQR) change from baseline to week 8 was –3.2 mg/L (–11.1, –1.0) and –1.1 mg/L (–7.1, 0.6) for TCZ and adalimumab, respectively (p=0.0077) (table 2 and figure 1A). </plain></SENT>
<SENT sid="162" pm="."><plain>Reductions in sPLA2 IIA levels were also observed with both TCZ and adalimumab monotherapy, with greater reductions seen in the TCZ group; median (IQR) change from baseline to week 8 was –4.1 ng/mL (–7.8, –1.1) and –1.3 ng/mL (–2.9, 0.8) for TCZ and adalimumab, respectively (p&lt;0.0001) (table 2 and figure 1B). </plain></SENT>
<SENT sid="163" pm="."><plain>Greater reductions in Lp(a) were observed in patients treated with TCZ monotherapy than with adalimumab monotherapy; the difference in adjusted means (95% CI) was –7.12 mg/dL (–9.9 to –4.4) (p&lt;0.0001) (table 3 and figure 1C). </plain></SENT>
<SENT sid="164" pm="."><plain>Higher proportions of patients who had baseline Lp(a) levels &gt;50 mg/dL improved (defined as achieving Lp(a) levels ≤50 mg/dL) by week 8 in the TCZ monotherapy group (11/21 patients (52.4%)) than in the adalimumab monotherapy group (6/24 patients (25.0%)). </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="ANNRHEUMDIS2015207872TB2" orientation="portrait" position="float"><label>Table 2</label><caption><p><text><SENT sid="165" pm="."><plain>Change from baseline to week 8* in HDL-SAA and sPLA2 IIA (bio-repository population) </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead valign="bottom"><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"><text><SENT sid="166" pm="."><plain>ADA 40 mg SC q2w, n=97 </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="167" pm="."><plain>TCZ 8 mg/kg IV q4w, n=87 </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="168" pm="."><plain>p Value† </plain></SENT>
</text></th></tr></thead><tbody><tr><td colspan="4" rowspan="1"><text><SENT sid="169" pm="."><plain>HDL-SAA (mg/L) </plain></SENT>
</text></td></tr><tr><td colspan="4" rowspan="1"><text><SENT sid="170" pm="."><plain> Baseline </plain></SENT>
</text></td></tr><tr><td rowspan="1" colspan="1"><text><SENT sid="171" pm="."><plain>  Median (IQR) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="172" pm="."><plain>7.8 (4.0, 16.8) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="173" pm="."><plain>6.9 (3.0, 13.9) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"><text><SENT sid="174" pm="."><plain>  Mean (SD) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="175" pm="."><plain>16.8 (23.6) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="176" pm="."><plain>13.0 (19.2) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="177" pm="."><plain>n=64 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="178" pm="."><plain>n=58 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr><td colspan="4" rowspan="1"><text><SENT sid="179" pm="."><plain> Change from baseline to week 8 </plain></SENT>
</text></td></tr><tr><td rowspan="1" colspan="1"><text><SENT sid="180" pm="."><plain>  Median (IQR) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="181" pm="."><plain>–1.1 (–7.1, 0.6) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="182" pm="."><plain>–3.2 (–11.1, –1.0) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="183" pm="."><plain>0.0077 </plain></SENT>
</text></td></tr><tr><td rowspan="1" colspan="1"><text><SENT sid="184" pm="."><plain>  Mean (SD) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="185" pm="."><plain>–4.4 (12.3) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="186" pm="."><plain>–9.3 (18.3) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="187" pm="."><plain>n=62 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="188" pm="."><plain>n=55 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr><td colspan="4" rowspan="1"><text><SENT sid="189" pm="."><plain>sPLA2 IIA (ng/mL) </plain></SENT>
</text></td></tr><tr><td colspan="4" rowspan="1"><text><SENT sid="190" pm="."><plain> Baseline </plain></SENT>
</text></td></tr><tr><td rowspan="1" colspan="1"><text><SENT sid="191" pm="."><plain>  Median (IQR) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="192" pm="."><plain>6.8 (5.1, 10.2) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="193" pm="."><plain>7.2 (4.7, 12.2) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"><text><SENT sid="194" pm="."><plain>  Mean (SD) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="195" pm="."><plain>10.7 (12.4) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="196" pm="."><plain>2.1 (14.8) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="197" pm="."><plain>n=90 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="198" pm="."><plain>n=77 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr><td colspan="4" rowspan="1"><text><SENT sid="199" pm="."><plain> Change from baseline to week 8 </plain></SENT>
</text></td></tr><tr><td rowspan="1" colspan="1"><text><SENT sid="200" pm="."><plain>  Median (IQR) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="201" pm="."><plain>–1.3 (–2.9, 0.8) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="202" pm="."><plain>–4.1 (–7.8, –1.1) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="203" pm="."><plain>&lt;0.0001 </plain></SENT>
</text></td></tr><tr><td rowspan="1" colspan="1"><text><SENT sid="204" pm="."><plain>  Mean (SD) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="205" pm="."><plain>–1.8 (9.15) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="206" pm="."><plain>–7.8 (12.8) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="207" pm="."><plain>n=86 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="208" pm="."><plain>n=73 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn><p><text><SENT sid="209" pm="."><plain>n represents number of patients contributing to summary statistics. </plain></SENT>
</text></p></fn><fn><p><text><SENT sid="210" pm="."><plain>*Includes only patients with both baseline and week 8 values. </plain></SENT>
</text></p></fn><fn><p><text><SENT sid="211" pm="."><plain>†Comparison between medians (ADA vs TCZ) using the Kruskal–Wallis test. </plain></SENT>
</text></p></fn><fn><p><text><SENT sid="212" pm="."><plain>ADA, adalimumab; HDL-SAA, high-density lipoprotein-associated serum amyloid A; IV, intravenous; q2w, every 2 weeks; q4w, every 4 weeks; SC, subcutaneous; sPLA2 IIA, secretory phospholipase A2 II; TCZ, tocilizumab. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="ANNRHEUMDIS2015207872TB3" orientation="portrait" position="float"><label>Table 3</label><caption><p><text><SENT sid="213" pm="."><plain>Change from baseline to week 8* in Lp(a) for all patients (safety population) </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead valign="bottom"><tr><th align="left" rowspan="1" colspan="1"><text><SENT sid="214" pm="."><plain>Subgroup </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="215" pm="."><plain>Statistic </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="216" pm="."><plain>ADA 40 mg SC q2w, n=162 </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="217" pm="."><plain>TCZ 8 mg/kg IV q4w, n=162 </plain></SENT>
</text></th></tr></thead><tbody><tr><td colspan="4" rowspan="1"><text><SENT sid="218" pm="."><plain>Lp(a) (mg/dL) </plain></SENT>
</text></td></tr><tr><td colspan="4" rowspan="1"><text><SENT sid="219" pm="."><plain> Baseline </plain></SENT>
</text></td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="220" pm="."><plain>n </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="221" pm="."><plain>162 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="222" pm="."><plain>162 </plain></SENT>
</text></td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="223" pm="."><plain>Mean (SD) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="224" pm="."><plain>25.5 (30.2) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="225" pm="."><plain>22.4 (25.5) </plain></SENT>
</text></td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="226" pm="."><plain>min, max </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="227" pm="."><plain>4.0, 194.0 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="228" pm="."><plain>4.0, 131.0 </plain></SENT>
</text></td></tr><tr><td colspan="4" rowspan="1"><text><SENT sid="229" pm="."><plain>Change from baseline to week 8 </plain></SENT>
</text></td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="230" pm="."><plain>n </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="231" pm="."><plain>157 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="232" pm="."><plain>156 </plain></SENT>
</text></td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="233" pm="."><plain>Mean (SD) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="234" pm="."><plain>–1.1 (15.1) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="235" pm="."><plain>–7.6 (12.0) </plain></SENT>
</text></td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="236" pm="."><plain>min, max </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="237" pm="."><plain>–102.5, 86.4 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="238" pm="."><plain>–60, 21.9 </plain></SENT>
</text></td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="239" pm="."><plain>Difference in adjusted means (95% CI)† </plain></SENT>
</text></td><td colspan="2" rowspan="1"><text><SENT sid="240" pm="."><plain>–7.12 (–9.9 to –4.4) </plain></SENT>
</text></td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="241" pm="."><plain>p Value‡ </plain></SENT>
</text></td><td colspan="2" rowspan="1"><text><SENT sid="242" pm="."><plain>&lt;0.0001 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn><p><text><SENT sid="243" pm="."><plain>*Includes only patients with both baseline and week 8 values. </plain></SENT>
</text></p></fn><fn><p><text><SENT sid="244" pm="."><plain>†Difference and 95% CI based on adjusted least square means (TCZ-ADA). </plain></SENT>
</text></p></fn><fn><p><text><SENT sid="245" pm="."><plain>‡ANCOVA model was adjusted for baseline Lp(a). p Values were unadjusted for multiple testing; therefore, no statistical significance can be claimed. </plain></SENT>
</text></p></fn><fn><p><text><SENT sid="246" pm="."><plain>ADA, adalimumab; ANCOVA, analysis of covariance; IV, intravenous; Lp(a), lipoprotein (a); q2w, every 2 weeks; q4w, every 4 weeks; SC, subcutaneous; TCZ, tocilizumab. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><SecTag type="FIG"><fig id="ANNRHEUMDIS2015207872F1" orientation="portrait" position="float"><label>Figure 1</label><caption><p><text><SENT sid="247" pm="."><plain>Change from baseline to week 8 in HDL-SAA (A, bio-repository population), sPLA2 IIA (B, bio-repository population) and Lp(a) (C, safety population)—patient-level data. </plain></SENT>
<SENT sid="248" pm="."><plain>ADA, adalimumab; HDL-SAA, high-density lipoprotein-associated serum amyloid A; IV, intravenous; Lp(a), lipoprotein (a); sPLA2 IIA, secretory phospholipase A2 IIA; q2w, every 2 weeks; q4w, every 4 weeks; SC, subcutaneous; TCZ, tocilizumab. </plain></SENT>
</text></p></caption><graphic xlink:href="annrheumdis-2015-207872f01"/></fig></SecTag><sec id="s3a"><title><text><SENT sid="249" pm="."><plain>Changes in HDL-SAA, sPLA2 IIA and Lp(a) levels by efficacy response </plain></SENT>
</text></title><p><text><SENT sid="250" pm="."><plain>Changes from baseline to week 8 in Lp(a), sPLA2 IIA and HDL-SAA were also evaluated relative to efficacy response. </plain></SENT>
<SENT sid="251" pm="."><plain>Greater reductions were seen in all three lipid-associated CV risk biomarkers at week 8 in both efficacy responders and non-responders who received TCZ monotherapy than in those who received adalimumab monotherapy. </plain></SENT>
<SENT sid="252" pm="."><plain>In ACR20 responders and non-responders, median IQR changes from baseline to week 8 in HDL-SAA were –3.3 mg/L (–10.0, –1.0) and –3.1 mg/L (–12.95, –1.15), respectively, with TCZ and –1.0 mg/L (–6.8, 0.55) and –1.1 mg/L (–8.7, 1.2), respectively, with adalimumab. </plain></SENT>
<SENT sid="253" pm="."><plain>Similar trends were observed for ACR50 and EULAR good/moderate responders and non-responders for HDL-SAA and for sPLA2 IIA (table 4) and Lp(a) (table 5). </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="ANNRHEUMDIS2015207872TB4" orientation="portrait" position="float"><label>Table 4</label><caption><p><text><SENT sid="254" pm="."><plain>Change from baseline to week 8* in HDL-SAA and sPLA2 IIA for week 24 ACR20, ACR50 and EULAR good/moderate responders and non-responders (bio-repository population) </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col span="1"/></colgroup><thead valign="bottom"><tr><th align="left" rowspan="1" colspan="1"><text><SENT sid="255" pm="."><plain>Subgroup </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="256" pm="."><plain>Statistic </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="257" pm="."><plain>ADA 40 mg SC q2w, n=97 </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="258" pm="."><plain>TCZ 8 mg/kg IV q4w, n=87 </plain></SENT>
</text></th></tr></thead><tbody><tr><td colspan="4" rowspan="1"><text><SENT sid="259" pm="."><plain>HDL-SAA change from baseline to week 8 (mg/L) </plain></SENT>
</text></td></tr><tr><td colspan="4" rowspan="1"><text><SENT sid="260" pm="."><plain> ACR20 responders </plain></SENT>
</text></td></tr><tr><td colspan="2" rowspan="1"><text><SENT sid="261" pm="."><plain>  n </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="262" pm="."><plain>32 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="263" pm="."><plain>39 </plain></SENT>
</text></td></tr><tr><td colspan="2" rowspan="1"><text><SENT sid="264" pm="."><plain>  Median (IQR) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="265" pm="."><plain>–1.0 (–6.8, 0.55) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="266" pm="."><plain>–3.3 (10.0, –1.0) </plain></SENT>
</text></td></tr><tr><td colspan="2" rowspan="1"><text><SENT sid="267" pm="."><plain>  Mean (SD) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="268" pm="."><plain>–5.8 (12.5) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="269" pm="."><plain>–10.3 (21.1) </plain></SENT>
</text></td></tr><tr><td colspan="4" rowspan="1"><text><SENT sid="270" pm="."><plain> ACR20 non-responders </plain></SENT>
</text></td></tr><tr><td colspan="2" rowspan="1"><text><SENT sid="271" pm="."><plain>  n </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="272" pm="."><plain>30 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="273" pm="."><plain>16 </plain></SENT>
</text></td></tr><tr><td colspan="2" rowspan="1"><text><SENT sid="274" pm="."><plain>  Median (IQR) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="275" pm="."><plain>–1.1 (–8.7, 1.2) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="276" pm="."><plain>–3.1 (–12.95, –1.15) </plain></SENT>
</text></td></tr><tr><td colspan="2" rowspan="1"><text><SENT sid="277" pm="."><plain>  Mean (SD) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="278" pm="."><plain>–2.9 (12.1) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="279" pm="."><plain>–7.1 (7.8) </plain></SENT>
</text></td></tr><tr><td colspan="4" rowspan="1"><text><SENT sid="280" pm="."><plain> ACR50 responders </plain></SENT>
</text></td></tr><tr><td colspan="2" rowspan="1"><text><SENT sid="281" pm="."><plain>  n </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="282" pm="."><plain>20 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="283" pm="."><plain>26 </plain></SENT>
</text></td></tr><tr><td colspan="2" rowspan="1"><text><SENT sid="284" pm="."><plain>  Median (IQR) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="285" pm="."><plain>–1.6 (–6.6, 0.25) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="286" pm="."><plain>–3.3 (–8.6, –1.0) </plain></SENT>
</text></td></tr><tr><td colspan="2" rowspan="1"><text><SENT sid="287" pm="."><plain>  Mean (SD) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="288" pm="."><plain>–5.1 (11.2) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="289" pm="."><plain>–11.8 (25.1) </plain></SENT>
</text></td></tr><tr><td colspan="4" rowspan="1"><text><SENT sid="290" pm="."><plain> ACR50 non-responders </plain></SENT>
</text></td></tr><tr><td colspan="2" rowspan="1"><text><SENT sid="291" pm="."><plain>  n </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="292" pm="."><plain>42 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="293" pm="."><plain>29 </plain></SENT>
</text></td></tr><tr><td colspan="2" rowspan="1"><text><SENT sid="294" pm="."><plain>  Median (IQR) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="295" pm="."><plain>–0.9 (–7.10, 0.7) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="296" pm="."><plain>–3.2 (–12.8, –1.0) </plain></SENT>
</text></td></tr><tr><td colspan="2" rowspan="1"><text><SENT sid="297" pm="."><plain>  Mean (SD) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="298" pm="."><plain>–4.0 (12.9) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="299" pm="."><plain>–7.2 (8.4) </plain></SENT>
</text></td></tr><tr><td colspan="4" rowspan="1"><text><SENT sid="300" pm="."><plain> EULAR good/moderate responders </plain></SENT>
</text></td></tr><tr><td colspan="2" rowspan="1"><text><SENT sid="301" pm="."><plain>  n </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="302" pm="."><plain>36 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="303" pm="."><plain>45 </plain></SENT>
</text></td></tr><tr><td colspan="2" rowspan="1"><text><SENT sid="304" pm="."><plain>  Median (IQR) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="305" pm="."><plain>–2.8 (–9.05, 0.5) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="306" pm="."><plain>–3.2 (–10.0, –1.0) </plain></SENT>
</text></td></tr><tr><td colspan="2" rowspan="1"><text><SENT sid="307" pm="."><plain>  Mean (SD) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="308" pm="."><plain>–6.2 (12.3) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="309" pm="."><plain>–9.6 (19.8) </plain></SENT>
</text></td></tr><tr><td colspan="4" rowspan="1"><text><SENT sid="310" pm="."><plain> EULAR non-responders </plain></SENT>
</text></td></tr><tr><td colspan="2" rowspan="1"><text><SENT sid="311" pm="."><plain>  n </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="312" pm="."><plain>26 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="313" pm="."><plain>10 </plain></SENT>
</text></td></tr><tr><td colspan="2" rowspan="1"><text><SENT sid="314" pm="."><plain>  Median (IQR) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="315" pm="."><plain>–0.5 (–5.7, 1.2) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="316" pm="."><plain>–2.9 (–18.2, –1.3) </plain></SENT>
</text></td></tr><tr><td colspan="2" rowspan="1"><text><SENT sid="317" pm="."><plain>  Mean (SD) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="318" pm="."><plain>–1.9 (12.1) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="319" pm="."><plain>–8.0 (8.9) </plain></SENT>
</text></td></tr><tr><td colspan="4" rowspan="1"><text><SENT sid="320" pm="."><plain>sPLA2 IIA change from baseline to week 8 (ng/mL) </plain></SENT>
</text></td></tr><tr><td colspan="4" rowspan="1"><text><SENT sid="321" pm="."><plain> ACR20 responders </plain></SENT>
</text></td></tr><tr><td colspan="2" rowspan="1"><text><SENT sid="322" pm="."><plain>  n </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="323" pm="."><plain>47 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="324" pm="."><plain>52 </plain></SENT>
</text></td></tr><tr><td colspan="2" rowspan="1"><text><SENT sid="325" pm="."><plain>  Median (IQR) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="326" pm="."><plain>–1.3 (–3.2, 0.7) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="327" pm="."><plain>–4.8 (–9.5, –1.3) </plain></SENT>
</text></td></tr><tr><td colspan="2" rowspan="1"><text><SENT sid="328" pm="."><plain>  Mean (SD) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="329" pm="."><plain>–1.6 (8.3) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="330" pm="."><plain>–9.5 (14.8) </plain></SENT>
</text></td></tr><tr><td colspan="4" rowspan="1"><text><SENT sid="331" pm="."><plain> ACR20 non-responders </plain></SENT>
</text></td></tr><tr><td colspan="2" rowspan="1"><text><SENT sid="332" pm="."><plain>  n </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="333" pm="."><plain>39 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="334" pm="."><plain>21 </plain></SENT>
</text></td></tr><tr><td colspan="2" rowspan="1"><text><SENT sid="335" pm="."><plain>  Median (IQR) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="336" pm="."><plain>–0.6 (–2.8, 1.9) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="337" pm="."><plain>–3.1 (–4.9, –1.0) </plain></SENT>
</text></td></tr><tr><td colspan="2" rowspan="1"><text><SENT sid="338" pm="."><plain>  Mean (SD) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="339" pm="."><plain>–2.0 (10.2) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="340" pm="."><plain>–3.7 (2.7) </plain></SENT>
</text></td></tr><tr><td colspan="4" rowspan="1"><text><SENT sid="341" pm="."><plain> ACR50 responders </plain></SENT>
</text></td></tr><tr><td colspan="2" rowspan="1"><text><SENT sid="342" pm="."><plain>  n </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="343" pm="."><plain>24 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="344" pm="."><plain>36 </plain></SENT>
</text></td></tr><tr><td colspan="2" rowspan="1"><text><SENT sid="345" pm="."><plain>  Median (IQR) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="346" pm="."><plain>–1.8 (–2.6, 0.2) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="347" pm="."><plain>–5.0 (–9.5, –0.95) </plain></SENT>
</text></td></tr><tr><td colspan="2" rowspan="1"><text><SENT sid="348" pm="."><plain>  Mean (SD) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="349" pm="."><plain>–1.6 (2.5) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="350" pm="."><plain>–9.7 (13.9) </plain></SENT>
</text></td></tr><tr><td colspan="4" rowspan="1"><text><SENT sid="351" pm="."><plain> ACR50 non-responders </plain></SENT>
</text></td></tr><tr><td colspan="2" rowspan="1"><text><SENT sid="352" pm="."><plain>  n </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="353" pm="."><plain>62 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="354" pm="."><plain>37 </plain></SENT>
</text></td></tr><tr><td colspan="2" rowspan="1"><text><SENT sid="355" pm="."><plain>  Median (IQR) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="356" pm="."><plain>–1.0 (–3.2, 1.4) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="357" pm="."><plain>–4.0 (–6.7, –1.5) </plain></SENT>
</text></td></tr><tr><td colspan="2" rowspan="1"><text><SENT sid="358" pm="."><plain>  Mean (SD) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="359" pm="."><plain>–1.9 (10.7) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="360" pm="."><plain>–6.1 (11.5) </plain></SENT>
</text></td></tr><tr><td colspan="4" rowspan="1"><text><SENT sid="361" pm="."><plain> EULAR good/moderate responders </plain></SENT>
</text></td></tr><tr><td colspan="2" rowspan="1"><text><SENT sid="362" pm="."><plain>  n </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="363" pm="."><plain>53 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="364" pm="."><plain>62 </plain></SENT>
</text></td></tr><tr><td colspan="2" rowspan="1"><text><SENT sid="365" pm="."><plain>  Median (IQR) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="366" pm="."><plain>–1.6 (–3.2, 0.7) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="367" pm="."><plain>–4.7 (–9.1, –1.1) </plain></SENT>
</text></td></tr><tr><td colspan="2" rowspan="1"><text><SENT sid="368" pm="."><plain>  Mean (SD) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="369" pm="."><plain>–2.2 (9.8) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="370" pm="."><plain>–8.7 (13.7) </plain></SENT>
</text></td></tr><tr><td colspan="4" rowspan="1"><text><SENT sid="371" pm="."><plain> EULAR non-responders </plain></SENT>
</text></td></tr><tr><td colspan="2" rowspan="1"><text><SENT sid="372" pm="."><plain>  n </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="373" pm="."><plain>33 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="374" pm="."><plain>11 </plain></SENT>
</text></td></tr><tr><td colspan="2" rowspan="1"><text><SENT sid="375" pm="."><plain>  Median (IQR) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="376" pm="."><plain>–0.2 (–2.1, 1.9) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="377" pm="."><plain>–2.7 (–6.0, –0.8) </plain></SENT>
</text></td></tr><tr><td colspan="2" rowspan="1"><text><SENT sid="378" pm="."><plain>  Mean (SD) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="379" pm="."><plain>–1.2 (8.1) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="380" pm="."><plain>–3.2 (2.4) </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn><p><text><SENT sid="381" pm="."><plain>n represents number of patients contributing to summary statistics. </plain></SENT>
</text></p></fn><fn><p><text><SENT sid="382" pm="."><plain>The range of data for each parameter is depicted in figure 1. </plain></SENT>
</text></p></fn><fn><p><text><SENT sid="383" pm="."><plain>*Includes only patients with both baseline and week 8 values. </plain></SENT>
</text></p></fn><fn><p><text><SENT sid="384" pm="."><plain>ACR, American College of Rheumatology; ADA, adalimumab; EULAR, European League against Rheumatism; HDL-SAA, high-density lipoprotein-associated serum amyloid-A; IV, intravenous; q2w, every 2 weeks; q4w, every 4 weeks; SC, subcutaneous; sPLA2 IIA, secretory phospholipase A2 IIA; TCZ, tocilizumab. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="ANNRHEUMDIS2015207872TB5" orientation="portrait" position="float"><label>Table 5</label><caption><p><text><SENT sid="385" pm="."><plain>Change from baseline to week 8* in Lp(a) for week 24 ACR20, ACR50 and EULAR good/moderate responders and non-responders (safety population) </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col span="1"/></colgroup><thead valign="bottom"><tr><th align="left" rowspan="1" colspan="1"><text><SENT sid="386" pm="."><plain>Subgroup </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="387" pm="."><plain>Statistic </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="388" pm="."><plain>ADA 40 mg SC q2w, n=162 </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="389" pm="."><plain>TCZ 8 mg/kg IV q4w, n=162 </plain></SENT>
</text></th></tr></thead><tbody><tr><td colspan="4" rowspan="1"><text><SENT sid="390" pm="."><plain>Lp(a) (mg/dL) change from baseline to week 8 </plain></SENT>
</text></td></tr><tr><td colspan="4" rowspan="1"><text><SENT sid="391" pm="."><plain> ACR20 responders </plain></SENT>
</text></td></tr><tr><td colspan="2" rowspan="1"><text><SENT sid="392" pm="."><plain>  n </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="393" pm="."><plain>79 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="394" pm="."><plain>104 </plain></SENT>
</text></td></tr><tr><td colspan="2" rowspan="1"><text><SENT sid="395" pm="."><plain>  Mean (SD) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="396" pm="."><plain>–2.5 (18.0) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="397" pm="."><plain>–8.1 (11.9) </plain></SENT>
</text></td></tr><tr><td colspan="2" rowspan="1"><text><SENT sid="398" pm="."><plain>  min, max </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="399" pm="."><plain>–102.5, 86.4 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="400" pm="."><plain>–60.0, 4.8 </plain></SENT>
</text></td></tr><tr><td colspan="4" rowspan="1"><text><SENT sid="401" pm="."><plain> ACR20 non-responders </plain></SENT>
</text></td></tr><tr><td colspan="2" rowspan="1"><text><SENT sid="402" pm="."><plain>  n </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="403" pm="."><plain>78 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="404" pm="."><plain>52 </plain></SENT>
</text></td></tr><tr><td colspan="2" rowspan="1"><text><SENT sid="405" pm="."><plain>  Mean (SD) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="406" pm="."><plain>0.3 (11.4) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="407" pm="."><plain>–6.5 (12.1) </plain></SENT>
</text></td></tr><tr><td colspan="2" rowspan="1"><text><SENT sid="408" pm="."><plain>  min, max </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="409" pm="."><plain>–22.0, 55.2 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="410" pm="."><plain>–53.6, 21.9 </plain></SENT>
</text></td></tr><tr><td colspan="4" rowspan="1"><text><SENT sid="411" pm="."><plain> ACR50 responders </plain></SENT>
</text></td></tr><tr><td colspan="2" rowspan="1"><text><SENT sid="412" pm="."><plain>  n </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="413" pm="."><plain>45 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="414" pm="."><plain>76 </plain></SENT>
</text></td></tr><tr><td colspan="2" rowspan="1"><text><SENT sid="415" pm="."><plain>  Mean (SD) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="416" pm="."><plain>–3.6 (7.2) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="417" pm="."><plain>–9.0 (13.0) </plain></SENT>
</text></td></tr><tr><td colspan="2" rowspan="1"><text><SENT sid="418" pm="."><plain>  min, max </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="419" pm="."><plain>–32.6, 6.3 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="420" pm="."><plain>–60.0, 4.8 </plain></SENT>
</text></td></tr><tr><td colspan="4" rowspan="1"><text><SENT sid="421" pm="."><plain> ACR50 non-responders </plain></SENT>
</text></td></tr><tr><td colspan="2" rowspan="1"><text><SENT sid="422" pm="."><plain>  n </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="423" pm="."><plain>112 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="424" pm="."><plain>80 </plain></SENT>
</text></td></tr><tr><td colspan="2" rowspan="1"><text><SENT sid="425" pm="."><plain>  Mean (SD) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="426" pm="."><plain>–0.1 (17.2) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="427" pm="."><plain>–6.2 (10.8) </plain></SENT>
</text></td></tr><tr><td colspan="2" rowspan="1"><text><SENT sid="428" pm="."><plain>  min, max </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="429" pm="."><plain>–102.5, 86.4 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="430" pm="."><plain>–53.6, 21.9 </plain></SENT>
</text></td></tr><tr><td colspan="4" rowspan="1"><text><SENT sid="431" pm="."><plain> EULAR good/moderate responders </plain></SENT>
</text></td></tr><tr><td colspan="2" rowspan="1"><text><SENT sid="432" pm="."><plain>  n </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="433" pm="."><plain>88 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="434" pm="."><plain>125 </plain></SENT>
</text></td></tr><tr><td colspan="2" rowspan="1"><text><SENT sid="435" pm="."><plain>  Mean (SD) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="436" pm="."><plain>–2.0 (17.8) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="437" pm="."><plain>–8.6 (12.6) </plain></SENT>
</text></td></tr><tr><td colspan="2" rowspan="1"><text><SENT sid="438" pm="."><plain>  min, max </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="439" pm="."><plain>–102.5, 86.4 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="440" pm="."><plain>–60.0, 4.8 </plain></SENT>
</text></td></tr><tr><td colspan="4" rowspan="1"><text><SENT sid="441" pm="."><plain> EULAR non-responders </plain></SENT>
</text></td></tr><tr><td colspan="2" rowspan="1"><text><SENT sid="442" pm="."><plain>  n </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="443" pm="."><plain>69 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="444" pm="."><plain>31 </plain></SENT>
</text></td></tr><tr><td colspan="2" rowspan="1"><text><SENT sid="445" pm="."><plain>  Mean (SD) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="446" pm="."><plain>–0.0 (10.8) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="447" pm="."><plain>–3.5 (7.8) </plain></SENT>
</text></td></tr><tr><td colspan="2" rowspan="1"><text><SENT sid="448" pm="."><plain>  min, max </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="449" pm="."><plain>–22.0, 55.2 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="450" pm="."><plain>–17.9, 21.9 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn><p><text><SENT sid="451" pm="."><plain>*Includes only patients with both baseline and week 8 values. </plain></SENT>
</text></p></fn><fn><p><text><SENT sid="452" pm="."><plain>ACR, American College of Rheumatology; ADA, adalimumab; EULAR, European League against Rheumatism; IV, intravenous; Lp(a), lipoprotein (a); q2w, every 2 weeks; q4w, every 4 weeks; SC, subcutaneous; TCZ, tocilizumab. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag></sec></sec></SecTag><SecTag type="DISCUSS"><sec sec-type="discussion" id="s4"><title><text><SENT sid="453" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="454" pm="."><plain>It was previously demonstrated that though LDL-C levels increase in patients treated with TCZ, Lp(a) levels may decline, and favourable changes in HDL-C level and HDL composition may occur.16 Published data regarding the effect of TNF-α blockers on Lp(a) are conflicting.19–22 Data collected in the ADACTA study allowed, for the first time, a direct comparison of the effect of anti-TNF (aTNF) and anti–IL-6 therapies on lipids and lipid-associated CV risk biomarkers in the context of a single study in which other trial parameters were balanced between groups by strict randomisation and blinding. </plain></SENT>
<SENT sid="455" pm="."><plain>Post-hoc analyses showed a greater increase in LDL-C and greater reductions in Lp(a), HDL-SAA and sPLA2 IIA levels over the first 8 weeks of treatment in patients with RA who received TCZ monotherapy compared with those who received adalimumab monotherapy. </plain></SENT>
<SENT sid="456" pm="."><plain>Reductions in HDL-SAA, sPLA2 IIA and Lp(a) were observed in efficacy responders and non-responders, suggesting that the cytokines themselves—as opposed to, or at least in addition to, other disease activity-related pathways—mediate some of the effects observed. </plain></SENT>
<SENT sid="457" pm="."><plain>Although reductions for both responders and non-responders treated with TCZ monotherapy appear to be larger than for those treated with adalimumab monotherapy, the small sample size for each group precludes statistical comparison. </plain></SENT>
</text></p><p><text><SENT sid="458" pm="."><plain>Increased inflammation in patients with autoimmune disorders such as RA is associated with quantitative and qualitative modifications of circulating lipids. </plain></SENT>
<SENT sid="459" pm="."><plain>Recent data suggest that decreased LDL-C and HDL-C levels in patients with active RA are associated with increased cholesterol catabolism rather than decreased synthesis, with the reverse true following treatment of inflammation.28 These data are somewhat reassuring. </plain></SENT>
<SENT sid="460" pm="."><plain>Nevertheless, it should be noted that parallel lipid kinetic data do not exist for TCZ or for aTNF therapies. </plain></SENT>
<SENT sid="461" pm="."><plain>In addition to quantitative changes, inflammation may be accompanied by changes in lipid particle size and protein composition that may result in a potentially pro-atherogenic lipid profile. </plain></SENT>
<SENT sid="462" pm="."><plain>In particular, SAA, sPLA2 IIA and cholesteryl ester transfer protein can remodel the lipid and protein composition of HDL particles.29 Association of HDL with SAA and sPLA2 IIA impairs antioxidative and atheroprotective capacity of HDL.30 Displacement of HDL cargo proteins that have antioxidant activity, such as apoA1 and paraoxonase 1, with these acute-phase reactants results in HDL particles with pro-oxidant capacity.31 SAA-containing HDL may be retained in the vascular matrix by vascular proteoglycans and may therefore not be available for the reverse cholesterol transport.32 </plain></SENT>
</text></p><p><text><SENT sid="463" pm="."><plain>Elevated Lp(a) levels can contribute to atherogenesis by depositing LDL-C in the intima of the vascular wall by the recruitment of inflammatory cells or the binding of proinflammatory oxidised phospholipids. </plain></SENT>
<SENT sid="464" pm="."><plain>Lp(a) shares structural homology with plasminogen and plasmin and has potentially prothrombotic and anti-fibrinolytic properties, which could promote clot stabilisation and thrombosis.27 Recent data suggest that Lp(a) is an independent genetic risk marker of CVD and is potentially causal.13 It has been recommended that desirable levels of Lp(a) for patients at intermediate or high risk of CVD/CHD are &lt;50 mg/dL.27 </plain></SENT>
</text></p><p><text><SENT sid="465" pm="."><plain>The observation that reductions in HDL-SAA, sPLA2 IIA and Lp(a) occurred in non-responders suggests that the reduction in these potentially pro-atherogenic proteins with TCZ may be, at least partially, independent of the RA treatment response, reflecting the effect of IL-6 blockade outside the joint. </plain></SENT>
<SENT sid="466" pm="."><plain>IL-6 is known to have an effect on the release of acute-phase proteins from hepatocytes; SAA is increased and apoA1 is decreased.31 33 Synthesis of Lp(a) is increased in response to IL-6 in cultured human hepatocytes through direct regulation of a response element in the Lp(a) promoter, an effect that was inhibited by TCZ.34 Therefore, the results of the current analysis may be explained by an effect of IL-6 inhibition that is independent of its anti-arthritic effect, similar to its effect on C reactive protein production.35 Decreases in HDL-SAA, sPLA2 IIA and Lp(a) levels also occurred in adalimumab non-responders; although they appeared to have occurred to a lesser extent than in TCZ non-responders, the numbers were too small to make a statistical comparison. </plain></SENT>
<SENT sid="467" pm="."><plain>In contrast, results from a recent cohort study of patients with RA treated with TNF-α inhibitors, including adalimumab, showed that HDL-SAA was significantly decreased and that ApoAII was increased in EULAR good responders but not in non-responders, suggesting that the changes were due to the anti-inflammatory effect of TNF-α inhibition.36 Furthermore, no change in Lp(a) levels was observed in patients with RA treated with adalimumab for 3 months, and adalimumab did not have a direct effect on Lp(a) promoter activity in human hepatocytes, as was observed with TCZ.34 The small number of patients in the current analysis preclude statistical comparison between responders and non-responders in each treatment group, and larger studies would be required to investigate mechanisms of IL-6 and TNF-α effects on HDL-SAA, sPLA2 IIA and Lp(a). </plain></SENT>
</text></p><p><text><SENT sid="468" pm="."><plain>Limitations of this data analysis from the ADACTA study are that it was conducted post-hoc and that the treatment duration analysed was relatively short. </plain></SENT>
<SENT sid="469" pm="."><plain>Longer-term effects on lipid changes were not investigated, though these same effects seen at week 8 have been seen previously with TCZ treatment out to 24 weeks;16 nevertheless, the effect on CV risk cannot be determined. </plain></SENT>
<SENT sid="470" pm="."><plain>It is unknown whether the changes in lipid profiles and the reductions in Lp(a), HDL-SAA and sPLA2 IIA levels observed with TCZ treatment and the differences observed in treatment with adalimumab will have any implications on CV risk in patients with RA. </plain></SENT>
<SENT sid="471" pm="."><plain>Results from meta-analyses of mostly observational studies suggest that aTNF therapy for RA is likely associated with a decreased CV risk despite increases in lipid levels.37 38 Although the risk of CV events with TCZ has not been determined, the number of CV events in the placebo-controlled periods of the core TCZ Phase III trials was low. </plain></SENT>
<SENT sid="472" pm="."><plain>In addition, long-term data available to date have shown a stable rate of CV events over time with TCZ exposure.25 Furthermore, risk of on-treatment major adverse CV events was found to be associated with control of disease activity, but not lipid changes, in a retrospective post-hoc analysis of pooled data from trials, though admittedly the number of adjudicated events was modest.39 Clearly, studies designed specifically to compare the effects of biologics on lipid changes and CV outcomes are still required. </plain></SENT>
</text></p><p><text><SENT sid="473" pm="."><plain>In conclusion, despite the overall increased LDL-C levels observed with TCZ compared with adalimumab, TCZ may potentially exert beneficial actions on HDL-SAA, sPLA2 IIA and Lp(a), suggesting that IL-6 blockade may work in different ways to influence CVD risk. </plain></SENT>
</text></p></sec></SecTag><SecTag type="SUPPL"><sec sec-type="supplementary-material"><title><text><SENT sid="474" pm="."><plain>Supplementary Material </plain></SENT>
</text></title><supplementary-material content-type="local-data" id="SD1"><caption><title><text><SENT sid="475" pm="."><plain>Web table </plain></SENT>
</text></title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="annrheumdis-2015-207872-s1.pdf" orientation="portrait" id="d35e1678" position="anchor"/></supplementary-material></sec></SecTag></body><back><fn-group><SecTag type="ACK_FUND"><fn><p><text4fund><text><SENT sid="476" pm="."><plain>Acknowledgements: F. Hoffmann-La Roche provided writing assistance (performed by Sara Duggan, PhD, and Meryl Mandle). </plain></SENT>
</text></text4fund></p></fn></SecTag><fn><p><text><SENT sid="478" pm="."><plain>Contributors: CG, KT and MK were involved in the conception and design of the study. </plain></SENT>
<SENT sid="479" pm="."><plain>CG, IBM, AK, KT, MK, JP and NS were involved in the analysis and interpretation of the data. </plain></SENT>
<SENT sid="480" pm="."><plain>CG, NS, KT and JP wrote the initial draft of the manuscript. </plain></SENT>
<SENT sid="481" pm="."><plain>All authors drafted the article or revised it critically for important intellectual content; all authors approved the final version to be submitted for publication and all authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. </plain></SENT>
</text></p></fn><SecTag type="ACK_FUND"><fn><p><text4fund><text><SENT sid="482" pm="."><plain>Funding: F. Hoffmann-La Roche provided funding for writing assistance. </plain></SENT>
</text></text4fund></p></fn></SecTag><SecTag type="ACK_FUND"><fn><p><text4fund><text><SENT sid="484" pm="."><plain>Competing interests: CG has received fees for speaking and/or consulting from AbbVie, BMS, Roche, Pfizer, Celgene, MSD, Janssen and AB2 Bio, and he has received research funding from Roche, AbbVie, MSD and AB2 Bio. </plain></SENT>
<SENT sid="485" pm="."><plain>IBM has received grants and personal fees from Roche (during the conduct of the study), Pfizer, UCB, BMS, AbbVie and Amgen (outside the submitted work). </plain></SENT>
<SENT sid="486" pm="."><plain>AK has received grants from Roche (outside the submitted work). </plain></SENT>
<SENT sid="487" pm="."><plain>KT is an employee of Roche Products and owns share options in Roche. </plain></SENT>
<SENT sid="488" pm="."><plain>MK is an employee of Genentech and owns share options in Roche. </plain></SENT>
<SENT sid="489" pm="."><plain>JP is an employee of Roche Products and owns share options in Roche. </plain></SENT>
<SENT sid="490" pm="."><plain>NS has received fees for consulting from Roche, UCB and Sanofi/Regeneron and for speaking from Janssen. </plain></SENT>
</text></text4fund></p></fn></SecTag><fn><p><text><SENT sid="491" pm="."><plain>Provenance and peer review: Not commissioned; externally peer reviewed. </plain></SENT>
</text></p></fn></fn-group><SecTag type="REF"><ref-list><title>References</title><ref id="R1"><text><SENT sid="492" pm="."><plain>1SolomonDH, GoodsonNJ, KatzJN, et al Patterns of cardiovascular risk in rheumatoid arthritis. Ann Rheum Dis 2006;65:1608–12. 10.1136/ard.2005.05037716793844 </plain></SENT>
</text></ref><ref id="R2"><text><SENT sid="493" pm="."><plain>2Aviña-ZubietaJA, ChoiHK, SadatsafaviM, et al Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008;59:1690–7. 10.1002/art.2409219035419 </plain></SENT>
</text></ref><ref id="R3"><text><SENT sid="494" pm="."><plain>3del RincónI, WilliamsK, SternMP, et al High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001;44:2737–45. 10.1002/1529-0131(200112)44:12&lt;2737::AID-ART460&gt;3.0.CO;2-#11762933 </plain></SENT>
</text></ref><ref id="R4"><text><SENT sid="495" pm="."><plain>4SattarN, McCareyDW, CapellH, et al Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003;108:2957–63. 10.1161/01.CIR.0000099844.31524.0514676136 </plain></SENT>
</text></ref><ref id="R5"><text><SENT sid="496" pm="."><plain>5MyasoedovaE, CrowsonCS, KremersHM, et al Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis 2011;70:482–7. 10.1136/ard.2010.13587121216812 </plain></SENT>
</text></ref><ref id="R6"><text><SENT sid="497" pm="."><plain>6KugiyamaK, OtaY, TakazoeK, et al Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease. Circulation 1999;100:1280–4. 10.1161/01.CIR.100.12.128010491371 </plain></SENT>
</text></ref><ref id="R7"><text><SENT sid="498" pm="."><plain>7RidkerPM, HennekensCH, BuringJE, et al C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836–43. 10.1056/NEJM20000323342120210733371 </plain></SENT>
</text></ref><ref id="R8"><text><SENT sid="499" pm="."><plain>8MallatZ, BenessianoJ, SimonT, et al Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women: the EPIC-Norfolk study. Arterioscler Thromb Vasc Biol 2007;27:1177–83. 10.1161/ATVBAHA.107.13935217303774 </plain></SENT>
</text></ref><ref id="R9"><text><SENT sid="500" pm="."><plain>9RobertsonJ, PetersMJ, McInnesIB, et al Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm. Nat Rev Rheumatol 2013;9:513–23. 10.1038/nrrheum.2013.9123774906 </plain></SENT>
</text></ref><ref id="R10"><text><SENT sid="501" pm="."><plain>10LeeYH, ChoiSJ, JiJD, et al Lipoprotein(a) and lipids in relation to inflammation in rheumatoid arthritis. Clin Rheumatol 2000;19:324–5. 10.1007/PL0001117410941819 </plain></SENT>
</text></ref><ref id="R11"><text><SENT sid="502" pm="."><plain>11ClarkeR, PedenJF, HopewellJC, et al Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009;361:2518–28. 10.1056/NEJMoa090260420032323 </plain></SENT>
</text></ref><ref id="R12"><text><SENT sid="503" pm="."><plain>12KamstrupPR, Tybjærg-HansenA, NordestgaardBG Genetic evidence that lipoprotein(a) associates with atherosclerotic stenosis rather than venous thrombosis. Arterioscler Thromb Vasc Biol 2012;32:1732–41. 10.1161/ATVBAHA.112.24876522516069 </plain></SENT>
</text></ref><ref id="R13"><text><SENT sid="504" pm="."><plain>13KamstrupPR, Tybjaerg-HansenA, SteffensenR, et al Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009;301:2331–9. 10.1001/jama.2009.80119509380 </plain></SENT>
</text></ref><ref id="R14"><text><SENT sid="505" pm="."><plain>14BoffaMB, KoschinskyML Update on lipoprotein(a) as a cardiovascular risk factor and mediator. Curr Atheroscler Rep 2013;15:360 10.1007/s11883-013-0360-623990263 </plain></SENT>
</text></ref><ref id="R15"><text><SENT sid="506" pm="."><plain>15ChoyE, SattarN Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis 2009;68:460–9. 10.1136/ard.2008.10196419286905 </plain></SENT>
</text></ref><ref id="R16"><text><SENT sid="507" pm="."><plain>16McInnesIB, ThompsonL, GilesJT, et al Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Ann Rheum Dis 2015;74:694–702. 10.1136/annrheumdis-2013-20434524368514 </plain></SENT>
</text></ref><ref id="R17"><text><SENT sid="508" pm="."><plain>17DaïenCI, DunyY, BarnetcheT, et al Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis. Ann Rheum Dis 2012;71:862–8. 10.1136/annrheumdis-2011-20114822267329 </plain></SENT>
</text></ref><ref id="R18"><text><SENT sid="509" pm="."><plain>18PopaC, NeteaMG, RadstakeT, et al Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheum Dis 2005;64:303–5. 10.1136/ard.2004.02311915231512 </plain></SENT>
</text></ref><ref id="R19"><text><SENT sid="510" pm="."><plain>19WijbrandtsCA, van LeuvenSI, BoomHD, et al Sustained changes in lipid profile and macrophage migration inhibitory factor levels after anti-tumour necrosis factor therapy in rheumatoid arthritis. Ann Rheum Dis 2009;68:1316–21. 10.1136/ard.2007.08672818723565 </plain></SENT>
</text></ref><ref id="R20"><text><SENT sid="511" pm="."><plain>20CauzaE, CauzaK, Hanusch-EnsererU, et al Intravenous anti TNF-alpha antibody therapy leads to elevated triglyceride and reduced HDL-cholesterol levels in patients with rheumatoid and psoriatic arthritis. Wien Klin Wochenschr 2002;114:1004–7.12635469 </plain></SENT>
</text></ref><ref id="R21"><text><SENT sid="512" pm="."><plain>21SerioloB, PaolinoS, SulliA, et al Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis. Ann N Y Acad Sci 2006;1069:414–19. 10.1196/annals.1351.03916855168 </plain></SENT>
</text></ref><ref id="R22"><text><SENT sid="513" pm="."><plain>22HjeltnesG, HollanI, FørreO, et al Serum levels of lipoprotein(a) and E-selectin are reduced in rheumatoid arthritis patients treated with methotrexate or methotrexate in combination with TNF-alpha-inhibitor. Clin Exp Rheumatol 2013;31:415–21.23465067 </plain></SENT>
</text></ref><ref id="R23"><text><SENT sid="514" pm="."><plain>23SattarN, CromptonP, CherryL, et al Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: a double-blind, placebo-controlled study. Arthritis Rheum 2007;56:831–9. 10.1002/art.2244717328057 </plain></SENT>
</text></ref><ref id="R24"><text><SENT sid="515" pm="."><plain>24GabayC, EmeryP, van VollenhovenR, et al Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 2013;381:1541–50. 10.1016/S0140-6736(13)60250-023515142 </plain></SENT>
</text></ref><ref id="R25"><text><SENT sid="516" pm="."><plain>25SchiffMH, KremerJM, JahreisA, et al Integrated safety in tocilizumab clinical trials. Arthritis Res Ther 2011;13:R141 10.1186/ar345521884601 </plain></SENT>
</text></ref><ref id="R26"><text><SENT sid="517" pm="."><plain>26ChibaH, AkizawaK, FujisawaS, et al A rapid and simple quantification of human apolipoprotein E-rich high-density lipoproteins in serum. Biochem Med Metabolic Biol 1992;47:31–7. 10.1016/0885-4505(92)90005-J </plain></SENT>
</text></ref><ref id="R27"><text><SENT sid="518" pm="."><plain>27NordestgaardBG, ChapmanMJ, RayK, et al Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010;31:2844–53. 10.1093/eurheartj/ehq38620965889 </plain></SENT>
</text></ref><ref id="R28"><text><SENT sid="519" pm="."><plain>28Charles-SchoemanC, FleischmannR, DavignonJ, et al Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib. Arthritis Rheumatol 2015;67:616–25. 10.1002/art.3897425470338 </plain></SENT>
</text></ref><ref id="R29"><text><SENT sid="520" pm="."><plain>29JahangiriA, de BeerMC, NoffsingerV, et al HDL remodeling during the acute phase response. Arterioscler Thromb Vasc Biol 2009;29:261–7. 10.1161/ATVBAHA.108.17868119008529 </plain></SENT>
</text></ref><ref id="R30"><text><SENT sid="521" pm="."><plain>30RohrerL, HersbergerM, von EckardsteinA High density lipoproteins in the intersection of diabetes mellitus, inflammation and cardiovascular disease. Curr Opin Lipidol 2004;15:269–78. 10.1097/00041433-200406000-0000615166782 </plain></SENT>
</text></ref><ref id="R31"><text><SENT sid="522" pm="."><plain>31KhovidhunkitW, KimMS, MemonRA, et al Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 2004;45:1169–96. 10.1194/jlr.R300019-JLR20015102878 </plain></SENT>
</text></ref><ref id="R32"><text><SENT sid="523" pm="."><plain>32ChaitA, HanCY, OramJF, et al Thematic review series: the immune system and atherogenesis. </plain></SENT>
<SENT sid="524" pm="."><plain>Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease? J Lipid Res 2005;46:389–403.15722558 </plain></SENT>
</text></ref><ref id="R33"><text><SENT sid="525" pm="."><plain>33GabayC, KushnerI Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448–54. 10.1056/NEJM1999021134006079971870 </plain></SENT>
</text></ref><ref id="R34"><text><SENT sid="526" pm="."><plain>34MüllerN, SchulteDM, TürkK, et al IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans. J Lipid Res 2015;56:1034–42. 10.1194/jlr.P05220925713100 </plain></SENT>
</text></ref><ref id="R35"><text><SENT sid="527" pm="."><plain>35SmolenJS, AvilaJC, AletahaD Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction. Ann Rheum Dis 2012;71:687–93. 10.1136/annrheumdis-2011-20039522121130 </plain></SENT>
</text></ref><ref id="R36"><text><SENT sid="528" pm="."><plain>36JamnitskiA, LevelsJH, van den OeverIA, et al High-density lipoprotein profiling changes in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a cohort study. J Rheumatol 2013;40:825–30. 10.3899/jrheum.12135823637327 </plain></SENT>
</text></ref><ref id="R37"><text><SENT sid="529" pm="."><plain>37WestlakeSL, ColebatchAN, BairdJ, et al Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) 2011;50:518–31. 10.1093/rheumatology/keq31621071477 </plain></SENT>
</text></ref><ref id="R38"><text><SENT sid="530" pm="."><plain>38BarnabeC, MartinBJ, GhaliWA Systematic review and meta-analysis: anti-tumor necrosis factor alpha therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res 2011;63:522–9. 10.1002/acr.20371 </plain></SENT>
</text></ref><ref id="R39"><text><SENT sid="531" pm="."><plain>39RaoVU, PavlovA, KlearmanM, et al An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy. Arthritis Rheumatol 2015;67:372–80. 10.1002/art.3892025332171 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
